FR2516385A1 - Vaccin anti-aphteux et anti-colibacillaire et son procede de preparation - Google Patents
Vaccin anti-aphteux et anti-colibacillaire et son procede de preparation Download PDFInfo
- Publication number
- FR2516385A1 FR2516385A1 FR8121676A FR8121676A FR2516385A1 FR 2516385 A1 FR2516385 A1 FR 2516385A1 FR 8121676 A FR8121676 A FR 8121676A FR 8121676 A FR8121676 A FR 8121676A FR 2516385 A1 FR2516385 A1 FR 2516385A1
- Authority
- FR
- France
- Prior art keywords
- attachment
- vaccine
- antigen
- antigens
- aphthous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960005486 vaccine Drugs 0.000 title claims description 49
- 238000000034 method Methods 0.000 title claims description 11
- 239000000427 antigen Substances 0.000 claims abstract description 37
- 102000036639 antigens Human genes 0.000 claims abstract description 37
- 108091007433 antigens Proteins 0.000 claims abstract description 37
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000004473 Threonine Substances 0.000 claims abstract description 9
- 230000003612 virological effect Effects 0.000 claims abstract description 7
- 229940031416 bivalent vaccine Drugs 0.000 claims abstract 2
- 241000894006 Bacteria Species 0.000 claims description 12
- 108010067390 Viral Proteins Proteins 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000000725 suspension Substances 0.000 claims description 7
- 241000282887 Suidae Species 0.000 claims description 6
- 241000700605 Viruses Species 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 241000588724 Escherichia coli Species 0.000 claims description 5
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims description 5
- 101001123526 Ambrosia artemisiifolia Pectate lyase 4 Proteins 0.000 claims description 4
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 4
- 229930182490 saponin Natural products 0.000 claims description 4
- 150000007949 saponins Chemical class 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 101100248451 Arabidopsis thaliana RICE2 gene Proteins 0.000 claims description 2
- 206010028034 Mouth ulceration Diseases 0.000 claims 2
- 208000007117 Oral Ulcer Diseases 0.000 claims 2
- 230000003115 biocidal effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 12
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 8
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 7
- 238000002255 vaccination Methods 0.000 description 7
- 210000002845 virion Anatomy 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 241001124076 Aphididae Species 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101710188314 Protein V Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 231100000249 enterotoxic Toxicity 0.000 description 1
- 230000002242 enterotoxic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
- C12N2770/32134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Microbiology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8121676A FR2516385A1 (fr) | 1981-11-19 | 1981-11-19 | Vaccin anti-aphteux et anti-colibacillaire et son procede de preparation |
| DE8282402104T DE3264316D1 (en) | 1981-11-19 | 1982-11-18 | Vaccine against foot-and-mouth disease and colibacillosis, and process for preparing it |
| ES517461A ES517461A0 (es) | 1981-11-19 | 1982-11-18 | Procedimiento de preparacion de una vacuna bivalente contra la fiebre aftosa y anticolibacilar. |
| EP82402104A EP0080412B1 (fr) | 1981-11-19 | 1982-11-18 | Vaccin anti-aphteux et anti-colibacillaire et son procédé de préparation |
| ZA828574A ZA828574B (en) | 1981-11-19 | 1982-11-19 | Bivalent foot and mouth disease and colibacillose vaccine and method of preparing it |
| AR291359A AR229624A1 (es) | 1981-11-19 | 1982-11-19 | Procedimiento para la preparacion de una vacuna bivalente anti-aftosa y anticolibacilar |
| IN54/CAL/83A IN155663B (enExample) | 1981-11-19 | 1983-01-13 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8121676A FR2516385A1 (fr) | 1981-11-19 | 1981-11-19 | Vaccin anti-aphteux et anti-colibacillaire et son procede de preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2516385A1 true FR2516385A1 (fr) | 1983-05-20 |
| FR2516385B1 FR2516385B1 (enExample) | 1984-02-10 |
Family
ID=9264165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8121676A Granted FR2516385A1 (fr) | 1981-11-19 | 1981-11-19 | Vaccin anti-aphteux et anti-colibacillaire et son procede de preparation |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0080412B1 (enExample) |
| AR (1) | AR229624A1 (enExample) |
| DE (1) | DE3264316D1 (enExample) |
| ES (1) | ES517461A0 (enExample) |
| FR (1) | FR2516385A1 (enExample) |
| IN (1) | IN155663B (enExample) |
| ZA (1) | ZA828574B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK219084D0 (da) * | 1984-05-02 | 1984-05-02 | Frederik Carl Peter Lindberg | Antigen |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1488212A (fr) * | 1964-06-22 | 1967-07-13 | Behringwerke Ag | Procédé permettant d'atténuer le virus de la fièvre aphteuse |
| FR2025241A1 (en) * | 1968-12-04 | 1970-09-04 | Merieux Inst | Vaccine for foot and mouth disease and brucellosis |
| US4140763A (en) * | 1976-09-08 | 1979-02-20 | The United States Of America As Represented By The Secretary Of Agriculture | Vaccine for foot and mouth disease |
| US4298597A (en) * | 1979-09-04 | 1981-11-03 | University Of Saskatchewan | Vaccine for diarrhea caused by E. coli |
-
1981
- 1981-11-19 FR FR8121676A patent/FR2516385A1/fr active Granted
-
1982
- 1982-11-18 ES ES517461A patent/ES517461A0/es active Granted
- 1982-11-18 DE DE8282402104T patent/DE3264316D1/de not_active Expired
- 1982-11-18 EP EP82402104A patent/EP0080412B1/fr not_active Expired
- 1982-11-19 ZA ZA828574A patent/ZA828574B/xx unknown
- 1982-11-19 AR AR291359A patent/AR229624A1/es active
-
1983
- 1983-01-13 IN IN54/CAL/83A patent/IN155663B/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1488212A (fr) * | 1964-06-22 | 1967-07-13 | Behringwerke Ag | Procédé permettant d'atténuer le virus de la fièvre aphteuse |
| FR2025241A1 (en) * | 1968-12-04 | 1970-09-04 | Merieux Inst | Vaccine for foot and mouth disease and brucellosis |
| US4140763A (en) * | 1976-09-08 | 1979-02-20 | The United States Of America As Represented By The Secretary Of Agriculture | Vaccine for foot and mouth disease |
| US4298597A (en) * | 1979-09-04 | 1981-11-03 | University Of Saskatchewan | Vaccine for diarrhea caused by E. coli |
Non-Patent Citations (1)
| Title |
|---|
| EXBK/78 * |
Also Published As
| Publication number | Publication date |
|---|---|
| ES8307499A1 (es) | 1983-08-01 |
| AR229624A1 (es) | 1983-09-30 |
| ES517461A0 (es) | 1983-08-01 |
| EP0080412A1 (fr) | 1983-06-01 |
| EP0080412B1 (fr) | 1985-06-19 |
| DE3264316D1 (en) | 1985-07-25 |
| ZA828574B (en) | 1984-03-28 |
| IN155663B (enExample) | 1985-02-23 |
| FR2516385B1 (enExample) | 1984-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Francis | Recent advances in vaccine technologies | |
| EP0090886B1 (en) | Stabilization of influenza virus vaccine | |
| CZ20002819A3 (en) | Conjugate of strategically modified hepatitis B core protein, particles thereof, inoculum and method of inducting antibodies | |
| JPH05328967A (ja) | Ａｉｄｓワクチン及びその製法 | |
| EP0048201B1 (en) | Herpes simplex type i fraction vaccine and process for its preparation | |
| CN109820834B (zh) | 一种口蹄疫灭活病毒的保护剂及微胶囊疫苗的制备方法 | |
| JP2021501761A (ja) | ネコ白血病ウイルスワクチン | |
| EA006433B1 (ru) | Способ получения поверхностного антигена вируса гепатита b и содержащие его вакцинные композиции | |
| Svennerholm et al. | Antibody responses to live and killed poliovirus vaccines in the milk of Pakistani and Swedish women | |
| JP2021501757A (ja) | 狂犬病ウイルスワクチン | |
| JPH09110719A (ja) | 実質的には非宿主アルブミンを含有しないアジユバント化ワクチン | |
| US4470967A (en) | Lectin-containing anti-viral vaccines for domestic animals and method of preparation | |
| FR2466251A1 (fr) | Vaccin animal anticolibacillaire, obtention et application | |
| FR2516385A1 (fr) | Vaccin anti-aphteux et anti-colibacillaire et son procede de preparation | |
| AU2008272428B2 (en) | Adaptation of Pitman Moore strain of rabies virus to Primary chick embryo fibroblast cell cultures | |
| FR2575655A1 (fr) | Utilisation d'un interferon a faibles doses notamment pour regler l'appetit et l'efficacite de l'utilisation des aliments | |
| JPS62267239A (ja) | 複合ワクチン | |
| US5733550A (en) | Method for enhancing the association of exogenous peptides with class I MHC molecules on the surface of antigen presenting cells with β-microglobulin | |
| Damjanov et al. | Embryo-derived teratocarcinomas elicit splenomegaly in syngeneic host | |
| Semprevivo | Exometabolites of Leishmania donovani promastigotes. I. Isolation and initial characterization | |
| US20220211839A1 (en) | Feline leukemia virus vaccine | |
| US4540669A (en) | Herpes simplex type I subunit vaccine | |
| CN1221568C (zh) | 检测和治疗获得性免疫缺陷综合症的组合物和方法 | |
| FR2487201A2 (fr) | Preparation lymphocytaires applicables en therapeutique humaine, procede d'obtention et applications | |
| JPWO2009004900A1 (ja) | ユビキノン含有免疫アジュバント |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |